Immunkontrollpunkthemmere er en klasse legemidler som kjemper med kroppens immunsystem for å bekjempe kreftceller. De fleste pasienter reagerer imidlertid ikke på disse behandlingene. Det er en nyere klasse medikamenter som retter seg mot to proteiner som er involvert i å undertrykke kroppens immunrespons mot svulster.
Phase I of clinical trials has shown some exciting results, which were conducted in 19 patients suffering from kreft with the molecule M7824. These researchers are also undertaking trials with those suffering from bukspyttkjertelkreft and those infected with HPV.
There are many other trials and experiments being taken to treat and kreftkur more effectively in different research institutes. This drug with a dual approach will be a boon in the behandling av kreft, as with a single molecule, multiple therapies are included.